Short answer
Organon & Co (OGN) filed an 8-K current report with the SEC on October 30, 2026 reporting Item EX-99.1 (Exhibit EX-99.1), Item 7.01 (Regulation FD Disclosure). Q3 2026 results covered quarter ended September 30, 2026, with GAAP disclosures in the Form 10-Q.
Organon & Co 8-K event analysis
AI summary of each reported item and its exhibits
Item 7.01 · Regulation FD Disclosure
- Q3 2026 results covered quarter ended September 30, 2026, with GAAP disclosures in the Form 10-Q
- Supplemental non-GAAP metrics furnished in Exhibit 99.1 for investor analysis alongside GAAP results
- Pending Sun Pharmaceutical merger: Organon suspended its customary earnings release and conference call format
Item EX-99.1 · Exhibit EX-99.1
- Q3 2026 adjusted net income $256M, down from $263M; adjusted diluted EPS $0.94 versus $1.01
- Nine-month adjusted net income $674M, down from $789M; adjusted diluted EPS $2.51 versus $3.03
- Adjusted EBITDA $502M, down from $518M; margin 31.9% versus 32.3%
- Nine-month adjusted EBITDA $1,378M, down from $1,524M; margin 30.0% versus 32.4%
- Q3 adjusted EBITDA included $19M tied to the pending Sun Pharmaceutical transaction
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Organon & Co 8-K filings
Get the next OGN 8-K as it lands
Follow OGN for push alerts, or ask the research agent what this filing means.